Navigation Links
Microbia Announces Positive Phase 2 Results for Its Investigational,Compound Linaclotide

e="float:right; position: relative;">

"We are pleased that these results complement our previous study with linaclotide in patients suffering from chronic constipation," said Mark Currie, Ph.D., Microbia's senior vice president of research and development. "These data greatly expand our understanding of the potential beneficial actions of linaclotide in patients with lower bowel dysfunction and provide an impetus to advance this agent in later stage clinical development."

About Linaclotide

Linaclotide is a first-in-class compound currently being tested for the treatment of IBS-C, CC and other gastrointestinal disorders. Linaclotide is an agonist of guanylate cyclase type-C, a receptor found on the lining of the intestine. In preclinical testing linaclotide was shown to increase fluid secretion into the intestine, accelerate intestinal transit, and decrease visceral pain. Linaclotide was designed to exert its effect on the intestine with minimal systemic exposure. In Phase 1 testing linaclotide was well tolerated and was not detected in the systemic circulation of healthy subjects. Linaclotide is currently being studied in a pair of Phase 2 dose- ranging trials for IBS-C and CC.

About Irritable Bowel Syndrome (IBS)

One out of six adults in developed countries suffers from IBS, a chronic condition marked by abdominal pain and disturbed bowel function. Patients with IBS often have altered patterns of gastrointestinal motility which contribute to symptoms. Colonic transit that is too rapid results in diarrhea, while delayed colonic transit results in constipation. IBS accounts for 12% of adult visits to primary care physicians and is the most common disorder diagnosed by gastroenterologists. Health care costs associated with IBS exceed $25 billion annually. IBS patients fall into three subgroups-constipation-predominant (IBS-C), diarrhea-predominant (IBS-D), and alternating (IBS-A)-and 30% to 40% of these patients suffer from IBS-C.
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:7/23/2014)... 2014  Researchers from the North American Menopause Society ... calcium levels too high, 1 putting women at ... Women close to menopause are commonly told to ... diseases such as osteoporosis, to which they are particularly ... how much calcium they typically get through their food ...
(Date:7/23/2014)... ORLANDO, Fla. , July 23, 2014 /PRNewswire/ ... with Pharm Fresh Media. This integration provides pharmacies ... media to current and prospective patients. ... pharmacy and local consumer data to define target ... provides automated marketing capabilities available within the Digital ...
(Date:7/23/2014)... Global healthcare company GSK reports ... headwinds, increased price competition and supply disruptions to its ... points out that the company is very much in ... be confident about long-term prospects as well as the ... CFO Simon Dingemans adds that the company ...
Breaking Medicine Technology:Women Taking Too Much Calcium Create Health Risk 2Mevesi Enhances Solutions with Variable Print Media Capabilities! 2
... SPRINGS, Fla., Sept. 28 Tigris Pharmaceuticals, Inc., a ... the appointment of Mr. Neil Flanzraich as Executive Chairman ... of Mr. Flanzraich is a very important milestone for ... and CEO of Tigris, adding, "Neil brings to Tigris ...
... Research Group (MRG), the global authority on medical technology ... valued at $41 million in 2010, with revenues doubling ... issues surrounding obesity, coupled with an expanding patient pool ... growth in the gastric band market through 2015. This ...
Cached Medicine Technology:Tigris Pharmaceuticals Appoints Neil Flanzraich to Executive Chairman of the Board 2Tigris Pharmaceuticals Appoints Neil Flanzraich to Executive Chairman of the Board 3While Ethicon Endo-Surgery and Allergan Remain Front-Runners in the $41 Million Gastric Band Market, Other Competitors Battle for Third Place, According to Millennium Research Group 2
(Date:7/23/2014)... 2014 CarePoint Health is proud to ... New Jersey to receive the da Vinci® Xi™ Surgical ... the da Vinci series. This 4th generation robotic platform ... in innovation. The intuitive da Vinci Xi has broad ... of minimally invasive and complex surgical procedures. The acquisition ...
(Date:7/23/2014)... Recently, Agebc.com has launched its new ... is announcing a promotion of wedding dresses. According to ... at the end of this month. , The beautiful ... like A-line, mermaid, ball-gown, empire, and more. Agebc.com is ... special-occasion dresses for women, and the company is devoted ...
(Date:7/23/2014)... its latest blog post, Best Drug Rehabilitation , which ... during a stay in rehab can make a big difference ... on a topic that is quickly becoming among the most ... , The Best Drug Rehabilitation blog post on opiate abuse ... and why they’re considered “the mother of all Schedule II ...
(Date:7/23/2014)... The Europe Drilling fluid and Completion fluid Market Report defines ... Europe with analysis and forecast of revenue. The drilling fluid ... from around $1.3 billion in 2013 to $1.7 billion by ... , Browse through the TOC of the Europe drilling fluid ... the in-depth analysis provided. This also provides a glimpse of ...
(Date:7/23/2014)... 23, 2014 AidJoy is delighted to announce ... Zen on September 5, 2014 from 7:00 to ... supporters are expected to attend this semi-formal event. , "We ... the past six years," says Jess Dennis, Director of Operations ... reflect on this moment in AidJoy’s history before we launch ...
Breaking Medicine News(10 mins):Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 2Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 3Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 4Health News:Agebc.com Launched Its New Collection of Wedding Dresses 2Health News:Latest Best Drug Rehabilitation Blog Post Focuses on Opiate Abuse Facts 2Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 5Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 6Health News:AidJoy’s Inaugural Gala to be Held September 5, 2014 2
... Coaching Provides Caregiving Needed Resources and Coping Strategies , ... ... Leeza’s Place have teamed to provide online coaching for ... strategies. , , , , ,Working on concepts in “Take ...
... Networks, has joined Medeguide.com as Head of Advertising and Sponsorship ... ... Conrad, formerly Regional Managing Director for Admax Networks, has joined ... Medeguide,s online advertising and sponsorship activities. Medeguide is a new ...
... of information on multiple sclerosis medications and the financial help ... ... 2009 -- NeedyMeds, a national nonprofit, added a new resource page to ... page is a multiple sclerosis-specific source of help for those looking for ...
... Vega Tapped to Lead Health Care Improvement Firm,s Sales ... Associates, Inc. today announced the addition of Al Vega ... officer. Mr. Vega joins the company at a time ... sales and marketing efforts for the company. In particular, ...
... 20 The following is a statement of ... http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO )The Campaign ... (D-OR) for his leadership role in Senate committee ... and Drug Administration (FDA) regulatory authority over tobacco ...
... The following is a statement of Matthew ... http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO )The Campaign for ... for his leadership role in Senate committee approval ... Drug Administration (FDA) regulatory authority over tobacco products, ...
Cached Medicine News:Health News:Hummingbird Coaching Partners with Leeza's Place to Help Caregivers “Take Your Oxygen First” 2Health News:Hummingbird Coaching Partners with Leeza's Place to Help Caregivers “Take Your Oxygen First” 3Health News:Senior Advertising Executive Joins Medeguide 2Health News:New Source of Information on Multiple Sclerosis Medications 2Health News:Press Ganey Names Chief Sales and Marketing Officer 2Health News:Sen. Jeff Merkley Votes to Protect America's Kids From Tobacco 2Health News:Sen. Jeff Merkley Votes to Protect America's Kids From Tobacco 3Health News:Sen. Christopher Dodd Leads Fight to Protect America's Kids From Tobacco 2Health News:Sen. Christopher Dodd Leads Fight to Protect America's Kids From Tobacco 3
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... Precision Hand Instruments were developed in surgeon's ... while still having an instrument with the ... the fear of the bending or breaking. ... manufactured to conform to the surgeon's hand. ...
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
Medicine Products: